Data from Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer

• DOI: 10.1158/0008-5472.c.6511723.v1
• Publication Date: 2023-03-31T05:41:40Z
• Authors: Marianna Cerasuolo; Federica Maccarin...; Daniela Coltrini; Ali Mokhtar Mahmoud; Viviana Marolda; Gaia Cristina Ghe...; Sara Rezzola; Arianna Giacomini; Luca Triggiani; Magdalena Kostrzewa; Roberta Verde; Debora Paris; Dominique Melck; Marco Presta; Alessia Ligresti; Roberto Ronca
• Keywords: Enzalutamide; Tramp

<div>Abstract<p>Enzalutamide (MDV3100) is a potent second-generation androgen receptor antagonist approved for the treatment of castration-resistant prostate cancer (CRPC) in chemotherapy-naïve as well patients previously exposed to chemotherapy. However, resistance enzalutamide and withdrawal syndrome have been reported. Thus, reliable integrated preclinical models are required elucidate mechanisms assess therapeutic settings that may delay or prevent onset resistance. In this study, multistage murine model TRAMP TRAMP-derived cells used extensively characterize <i>in vitro</i> vivo</i> response enzalutamide. The profile were characterized multiscale stochastic mathematical was proposed link evolution cancer. showed all strategies use result also combination therapies can enzalutamide, best scenario, eliminate disease. These results set basis exploitation “TRAMP-based platform” test novel approaches build further treat CRPC.</p><p><b>Significance:</b> Merging modeling with experimental data, study presents tool enzalutamide.</p></div>